About Jefferson Innovation


Name: Jefferson Innovation

925 Chestnut Street
Suite 110
Philadelphia, PA 19107

Contact Number(s):

We Are Jefferson

Reimagine is our commitment to raising the resources it takes to change the world in multiple, meaningful ways. We’re going to change the future for Philadelphia and beyond:

  • People Leading Optimistic Revolutions
  • Spaces that Heal and Inspire
  • Communities United for Health Equity
  • Discoveries that Improve Lives

Learn More ...

Our Companies

Jefferson has a long history of developing ideas into companies and commercializing breakthrough technologies. Here are just a few of our successes that started right here at Jefferson.


BioVaxys is a clinical stage biotechnology company, developing immunotherapeutic cancer vaccines targeting melanoma, ovarian cancer, and other solid tumor types.

152 West 57th Street, 24th Floor, New York NY 10019  |  610-977-2440 https://biovaxys.com

Bound Therapeutics

Bound Therapeutics is developing nucleic acid based therapeutics RNA inhibitors for triple negative breast cancer.

31 N Maple Avenue #256, Marlton NJ 08053  215-917-4687  |  https://www.boundtherapeutics.com

Capillary Biomedical

This medical device startup developing technologies for diabetes management. Preclinical animal studies in progress. Research funded by Juvenile Diabetes Research Association. Thomas Jefferson University students won first prize at 2016 Diabetes Technology Meeting. Capillary Biomedical was aquired by Tandem Diabetes Care in July of 2022.

8 Faraday, Suite B, Irvine CA 92618  |  833-277-2461  |  http://capillarybio.com


Circalux is a circadian-friendly lighting company designing lighting pods to meet the needs of overnight care providers in the hospital and home. Created by three medical students at Thomas Jefferson University, Circalights emit circadian-friendly wavelengths at intensities proven to be the least disruptive to melatonin, one of the body's main chemical cues for sleep. The devices are rechargeable and adjust their brightness according to user proximity.



Clementia is developing Palovarotene, a highly selective retinoic acid receptor gamma agonist as a potential treatment for fibrodysplasia ossificans progressiva (FOP), an ultra-rare and severely disabling genetic disease characterized by extra-skeletal bone formation in muscle and soft tissues. Successful Phase 2 double-blind trial of Palvarotene for FOP reported in October 2016. Phase III multi-center, open label, pivotal trial in design phase. Pipeline includes use of Palvarotene for Multiple Osteochondromas (MO) and for Dry Eye Disease. As of February 26, 2019. Clementia was acquired by the French drug maker Ipsen.

275 Grove Street, Suite 2-400, Auburndale MA 02466  |  844-940-3600  |  https://clementiapharma.com

Conatus Pharmaceuticals

As a biotechnology company Conatus is developing Emricasan as a first-in-class, orally active pancaspase protease inhibitor designed to reduce the activity of enzymes that mediate inflammation and cell death, or apoptosis. Emricasan has strong preclinical study results. DN-7314 granted Orphan Drug Designation for the treatment of primary sclerosing cholangitis (PSC) in June 2017.

16745 W. Bernardo Drive, Suite 200, San Diego CA 92127  |  858-376-2600  |  https://www.conatuspharma.com


Immunome is Series A funded in 2016 and 2017 tranches, to further develop therapeutics based on antigen-antibody pairs, using antibodies from patients raised against their own tumors. Developed by Thomas Jefferson University and MIT Whitehead Institute. Completed initial public offering in October of 2020.

665 Stockton Drive, Suite 300, Exton PA 19341  |  610-321-3700  |  http://immunome.com


A biotechnology company developing an antisense molecule targeted to glioblastomas (brain cancers). Now enrolling patients in Phase 1b trial.

40 W. Evergreen Avenue, Suite 101, Philadelphia PA 19118 215-392-2525 | http://www.imvax.com


MTTI is developing rabies virus-specific neutralizing human monoclonal antibodies for the post exposure prophylaxis of rabies.

610-738-7938 http://www.mtarget.com/mtti/fusiontech.html

NuView Life Sciences

NuView Life Sciences is developing an prostate cancer urine screen using VPAC1 molecular imaging agent. Pipeline includes in vivo breast and prostate imaging agents. They are a subsidiary US Radiopharmaceuticals is 85,000 sq ft FDA-registered, cGMP medical isotope manufacturing and distribution facilities.

1389 Center Drive, Suite 250, Park City UT 84098  |  888-902-7779  |  http://nuviewinfo.com


Prostagene is developing technology targeting CCR5 for the preventon of metastasis in many types of cancer.  Preclinical studies showed that CCR5 inhibitors dramatically blocked prostate cancer metastasis to the bones and brain of immune competent mice and blocked the spread of breast cancer to the lungs. (Acquired by CytoDyn November 2018)

100 Lancaster Avenue, Room 133, Wynnewood PA 19096  

RTM Vital Signs

RTM Vital Signs is developing real-time implantable cardiac and acoustic ventilation devices and monitoring systems based on technology developed at Thomas Jefferson University. Their innovative, patented technology is designed to continuously monitor arterial blood pressure waveform and other vital sign data of ambulatory patients with cardiovascular disease (hypertension, ischemic heart disease, valve disease, arrhythmias and CHF) and ambulatory patients at risk for a serious adverse event. Physicians, nurses, and emergency personnel can now track recorded vital sign data, see trends, determine the etiology of new patient symptoms, and understand the effectiveness of medical therapy.

439 Dreshertown Road, Fort Washington PA 19034  |  215-643-1286 https://rtmvitalsigns.com

Sonogen Medical, Inc.

Sonogen is working to commercialize its next generation ultrasonic bone fracture healing device. Recent animal trials conducted at Jefferson and the Mayo Clinic demonstrated that Sonogen's technology is highly effective for bone fracture healing.  Sonogen's device also delivers an innovative fracture healing assessment capability, helping ensure both patience compliance and healing efficacy.  Sonogen is currently seeking $2-10 million in Series A investment funding, to finalize the design, build, and clinical validation of its commercial device.



Sillajen is developing an oncolytic viral therapy called Pexa-Vec for treatment of liver cancer. Currently in Phase 3 trials for use of Pexa-Vec in combination with Sutent (sorafenib) in advanced liver cancer, expected to conclude in 2018. In advanced colorectal cancer, Sillajen in August 2017 announced a partnership with the National Cancer Institute to initiate clinical trials of Pexa-Vec in combination with immune checkpoint inhibitors.

450 Sansom Street, 2nd Floor, San Francisco CA 94111 415-281-8886 http://www.sillajen.com

Targeted Diagnostics & Therapeutics (TDT)

Targeted Diagnostics & Therapeutics is a biotechnology company, developing molecular diagnostics and therapeutics for the diagnosis and treatment of colorectal cancer and other gastrointestinal diseases. Successful Phase I clinical trial completed in 2015 of cancer vacine, showing safety, tolerability, and immunological efficacy in stage 1 and stage 2 colon cancer patients. Phase II trial planning and Orphan Drug Status Application underway in partnership with Viral Gene Inc.

1595 Paoli Pike, Suite 204, West Chester PA 19380  |  610-431-0800

Xilio Therapeutics

“Xilio” (pronounced “ex-il-ee-oh”) is derived from the Latin term Ex Nihilo, meaning creation or big-bang, and embodies the company’s vision to create transformative treatments for individuals living with cancer by unleashing the full power of highly potent immune therapies selectively in tumors.

Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines. Completed initial public offering in October of 2021.

Xilio Therapeutics, 828 Winter Street, Waltham, MA 02451 |  https://www.xiliotx.com/